News

Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic

After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NASDAQ: NVAX) are doubtlessly eager for the biotech to finally step out of the

Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo

One of the leading artificial intelligence (AI) stocks on the market was left far behind by investors on Tuesday. C3.ai (NYSE: AI) saw its share price crumble by almost 8% on the back of comments

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Nvidia (NASDAQ: NVDA) founder and CEO Jensen Huang recently participated in a fireside chat at the World Governments Summit in Dubai that was attended by delegates from 150 countries.

In a

Genetic-testing company 23andMe (NASDAQ: ME) is a household name, but does that make it a smart investment? After all, if the tangible health benefits of learning more about your genome are as

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

The semiconductor industry has been red-hot over the last few years, and it isn't just Nvidia and Advanced Micro Devices delivering substantial gains for investors. The digital economy is forever

Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and

Nvidia (NASDAQ: NVDA) was the best-performing stock in the entire S&P 500 last year. As of Feb. 7, it is also the best-performing stock so far this year.

At first glance, this accomplishment sounds

There hasn't been room for much organic growth in the cannabis industry, particularly in the Canadian market. That has led many marijuana producers to pursue acquisitions to bolster their top lines.

There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's

Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around

In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market